Examining the association between monthly migraine frequency and quality of life: Post hoc analyses of outcomes data from the topiramate migraine trials

被引：0
|
作者：
Diamond, M
Dahlof, C
Mao, L
Rupnow, M
Papadopoulos, G
Greenberg, S
机构：
[1] Diamond Headache Clin Ltd, Chicago, IL USA
[2] Inst Clin Neurosci, Gothenburg, Sweden
[3] Ortho McNeil Pharmaceut, Raritan, NJ USA
[4] Janssen Med Affairs LLC, Titusville, NJ USA
来源：
HEADACHE | 2005年 / 45卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：778 / 778
页数：1
相关论文
共 50 条
  • [1] Evaluating the association between baseline migraine frequency and the efficacy of topiramate in the pivotal migraine prevention trials
    Rothrock, J
    Mulleners, W
    Pfeil, J
    Schwalen, S
    HEADACHE, 2005, 45 (06): : 823 - 823
  • [2] Topiramate improves the quality of life of patients with migraine:: pooled data from three placebo-controlled, migraine prevention trials
    Loder, E
    Dahlöf, C
    Diamond, M
    Mao, L
    Rupnow, M
    Papadopoulos, G
    Greenberg, S
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S486 - S486
  • [3] Analyses of quality-of-life indicators from three placebo-controlled trials of topiramate for migraine prevention
    Diamond, M
    Dahlof, C
    Mao, L
    Rupnow, M
    Papadopoulos, G
    Greenberg, S
    HEADACHE, 2005, 45 (06): : 777 - 778
  • [4] Do migraine preventive medications enhance the efficacy of triptans? Analyses from topiramate migraine trials
    Dodick, D
    Hulihan, J
    Wu, S
    HEADACHE, 2005, 45 (06): : 820 - 820
  • [5] Do migraine preventive medications enhance the efficacy of triptans? Analyses from topiramate migraine trials
    Dodick, D
    Hulihan, J
    Wu, SC
    CEPHALALGIA, 2004, 24 (09) : 808 - 808
  • [6] Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis
    Dodick, D.
    Lipton, R.
    Nahas, S.
    Pozo-Rosich, P.
    McAllister, P.
    Mechtler, L.
    Ma, J.
    Dabruzzo, B.
    Dufek, M.
    Severt, L.
    Finnegan, M.
    Trugman, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [7] Monthly migraine days, acute medication use days, and migraine-specific quality of life in responders to atogepant: A post hoc analysis
    Dodick, D. W.
    Lipton, R. B.
    Nahas, S. J.
    Pozo-Rosich, P.
    McAllister, P.
    Mechtler, L. L.
    Ma, J.
    Dabruzzo, B. L.
    Dufek, M.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2022, 62 : 152 - 153
  • [8] Assessing the effect of topiramate on the quality of life of patients with migraine in three placebo-controlled, migraine prevention trials
    Dahlöf, C
    Diamond, M
    Mao, L
    Rupnow, M
    Papadopoulos, G
    Greenberg, S
    CEPHALALGIA, 2005, 25 (10) : 944 - 945
  • [9] Impact of monthly headache days on migraine-related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study
    Lipton, Richard B.
    Pozo-Rosich, Patricia
    Orr, Serena L.
    Reed, Michael L.
    Fanning, Kristina M.
    Dabruzzo, Brett
    Buse, Dawn C.
    HEADACHE, 2023, 63 (10): : 1448 - 1457
  • [10] EVALUATING THE CORRELATION BETWEEN MONTHLY MIGRAINE DAYS AND QUALITY-OF-LIFE: UTILITY ANALYSES TO INFORM A JAPANESE COST-EFFECTIVENESS MODEL FOR FREMANEZUMAB IN MIGRAINE
    Peterse, E.
    Bennison, C.
    Paris, J. J.
    Chatterjee, A.
    Wang, X.
    Kojima, Y.
    Yamato, K.
    VALUE IN HEALTH, 2022, 25 (01) : S2 - S3
12345